Intranasal pharmaceutical dosage forms comprising naloxone
John Strang, Denmark Hill (GB); Alexander Oksche, Limburg (DE); Stephen Harris, Stamford, CT (US); Kevin Smith, Cambridge (GB); and Lucie Helene Jeanne Mottier, Cambridge (GB)
Assigned to HARM REDUCTION THERAPEUTICS, INC., Bethesda, MD (US)
Filed by HARM REDUCTION THERAPEUTICS, INC., Bethesda, MD (US)
Filed on Apr. 23, 2021, as Appl. No. 17/238,509.
Application 17/238,509 is a continuation of application No. 16/549,838, filed on Aug. 23, 2019, granted, now 11,020,343.
Application 16/549,838 is a continuation of application No. 15/418,138, filed on Jan. 27, 2017, abandoned.
Application 15/418,138 is a continuation of application No. 14/084,551, abandoned, previously published as PCT/EP2012/058792, filed on May 11, 2012.
Claims priority of application No. 11166076 (EP), filed on May 13, 2011.
Prior Publication US 2021/0338574 A1, Nov. 4, 2021
1. An intranasal pharmaceutical dosage form comprising naloxone or a pharmaceutically acceptable salt thereof dissolved in an application fluid in a final concentration equivalent to between 13 mg naloxone HCl per ml application fluid and 66 mg naloxone HCl per ml application fluid.